These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 30831429)

  • 1. A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions.
    Ling S; Mangaoil R; Cleverley K; Sproule B; Puts M
    Drug Alcohol Depend; 2019 Apr; 197():168-182. PubMed ID: 30831429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid agonist treatment for pharmaceutical opioid dependent people.
    Nielsen S; Larance B; Degenhardt L; Gowing L; Kehler C; Lintzeris N
    Cochrane Database Syst Rev; 2016 May; (5):CD011117. PubMed ID: 27157143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies.
    Degenhardt L; Clark B; Macpherson G; Leppan O; Nielsen S; Zahra E; Larance B; Kimber J; Martino-Burke D; Hickman M; Farrell M
    Lancet Psychiatry; 2023 Jun; 10(6):386-402. PubMed ID: 37167985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women.
    Tran TH; Griffin BL; Stone RH; Vest KM; Todd TJ
    Pharmacotherapy; 2017 Jul; 37(7):824-839. PubMed ID: 28543191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
    Bishop B; Gilmour J; Deering D
    Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydrocodeine for detoxification and maintenance treatment in individuals with opiate use disorders.
    Carney T; Van Hout MC; Norman I; Dada S; Siegfried N; Parry CD
    Cochrane Database Syst Rev; 2020 Feb; 2(2):CD012254. PubMed ID: 32068247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child.
    Zedler BK; Mann AL; Kim MM; Amick HR; Joyce AR; Murrelle EL; Jones HE
    Addiction; 2016 Dec; 111(12):2115-2128. PubMed ID: 27223595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: A systematic review.
    Maglione MA; Raaen L; Chen C; Azhar G; Shahidinia N; Shen M; Maksabedian E; Shanman RM; Newberry S; Hempel S
    J Subst Abuse Treat; 2018 Jun; 89():28-51. PubMed ID: 29706172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
    Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.
    Yarborough BJ; Stumbo SP; McCarty D; Mertens J; Weisner C; Green CA
    Drug Alcohol Depend; 2016 Mar; 160():112-8. PubMed ID: 26796596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of opioid agonist treatment on mental health in patients with opioid use disorder: a systematic review and network meta-analysis of randomized clinical trials.
    Moazen-Zadeh E; Ziafat K; Yazdani K; Kamel MM; Wong JSH; Modabbernia A; Blanken P; Verthein U; Schütz CG; Jang K; Akhondzadeh S; Krausz RM
    Am J Drug Alcohol Abuse; 2021 May; 47(3):280-304. PubMed ID: 33780647
    [No Abstract]   [Full Text] [Related]  

  • 12. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.
    Fox AD; Maradiaga J; Weiss L; Sanchez J; Starrels JL; Cunningham CO
    Addict Sci Clin Pract; 2015 Jan; 10(1):2. PubMed ID: 25592182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada.
    Piske M; Thomson T; Krebs E; Hongdilokkul N; Bruneau J; Greenland S; Gustafson P; Karim ME; McCandless LC; Maclure M; Platt RW; Siebert U; Socías ME; Tsui JI; Wood E; Nosyk B
    BMJ Open; 2020 Sep; 10(9):e036102. PubMed ID: 32912944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short term health-related quality of life improvement during opioid agonist treatment.
    Nosyk B; Bray JW; Wittenberg E; Aden B; Eggman AA; Weiss RD; Potter J; Ang A; Hser YI; Ling W; Schackman BR
    Drug Alcohol Depend; 2015 Dec; 157():121-8. PubMed ID: 26511766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retention in opioid agonist treatment: a rapid review and meta-analysis comparing observational studies and randomized controlled trials.
    Klimas J; Hamilton MA; Gorfinkel L; Adam A; Cullen W; Wood E
    Syst Rev; 2021 Aug; 10(1):216. PubMed ID: 34362464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication-assisted treatment with buprenorphine: assessing the evidence.
    Thomas CP; Fullerton CA; Kim M; Montejano L; Lyman DR; Dougherty RH; Daniels AS; Ghose SS; Delphin-Rittmon ME
    Psychiatr Serv; 2014 Feb; 65(2):158-70. PubMed ID: 24247147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Six-Year Outcome of Opioid Maintenance Treatment in Heroin-Dependent Patients: Results from a Naturalistic Study in a Nationally Representative Sample.
    Soyka M; Strehle J; Rehm J; Bühringer G; Wittchen HU
    Eur Addict Res; 2017; 23(2):97-105. PubMed ID: 28376505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment retention, drug use and social functioning outcomes in those receiving 3 months versus 1 month of supervised opioid maintenance treatment. Results from the Super C randomized controlled trial.
    Holland R; Maskrey V; Swift L; Notley C; Robinson A; Nagar J; Gale T; Kouimtsidis C
    Addiction; 2014 Apr; 109(4):596-607. PubMed ID: 24304349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.
    Sadek J; Saunders J
    BMC Psychiatry; 2022 Jul; 22(1):516. PubMed ID: 35908052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency and correlates of sleep disturbance in methadone and buprenorphine-maintained patients.
    Dunn KE; Finan PH; Andrew Tompkins D; Strain EC
    Addict Behav; 2018 Jan; 76():8-14. PubMed ID: 28735039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.